Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Stocks · News reference
Investment firm H.C. Wainwright has initiated coverage on Savara Inc. with a Buy rating and a price target of $10.00 per share.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Savara Inc. granted equity-based inducement awards to seven new employees on November 10, 2026.
Savara Inc. has released new data demonstrating the treatment effects of its molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP) who exhibit mild diffusion impairment.
JP Morgan analyst Caroline Pocher initiates coverage on Savara (NASDAQ:SVRA) with a Overweight rating and announces Price Target of $12.
U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3